Outcomes of relapsed/refractory patients with IDH1/2 mutated AML treated with non-targeted therapy: results from the NCRI AML trials by Hills, R, Gale, R, Linch, D, Huntly, B, Papaemmanuil, E, Vyas, P, Burnett, A, Russell, N

“…American Society of Hematology…”

Molecular MRD status and outcome after transplantation in NPM1-mutated AML by Dillon, R, Hills, R, Freeman, S, Potter, N, Jovanovic, J, Ivey, A, Kanda, AS, Runglall, M, Foot, N, Valganon, M, Khwaja, A, Cavenagh, J, Smith, M, Ommen, HB, Overgaard, UM, Dennis, M, Knapper, S, Kaur, H, Taussig, D, Mehta, P, Raj, K, Novitzky-Basso, I, Nikolousis, E, Danby, R, Krishnamurthy, P, Hill, K, Finnegan, D, Alimam, S, Hurst, E, Johnson, P, Khan, A, Salim, R, Craddock, C, Spearing, R, Gilkes, A, Gale, R, Burnett, A, Russell, NH, Grimwade, D

“…American Society of Hematology…”

Therapy-Related Myeloid Neoplasms with Balanced Chromosome Rearrangements Frequently Arise from Pre-Existing Clonal Haematopoiesis by Dillon, R, Jovanovic, J, Potter, N, Foot, N, Ahearne, M, Jayne, S, Dennis, M, Hunter, A, Dyer, M, Vyas, P, Quek, L, Russell, N, Hills, R, Solomon, E, Grimwade, D

“…American Society of Hematology…”

No evidence that CD33 splicing SNP impacts the response to GO in younger adults with AML treated on UK MRC/NCRI trials by Gale, R, Popa, T, Wright, M, Khan, N, Freeman, S, Burnett, A, Russell, N, Hills, R, Linch, D

“…American Society of Hematology…”

Higher daunorubicin exposure benefits FLT3 mutated acute myeloid leukemia by Burnett, A, Russell, N, Hills, R

“…American Society of Hematology…”

Minimal/measurable residual disease in AML: a consensus document from the European LeukemiaNet MRD Working Party by Schuurhuis, G, Heuser, M, Freeman, S, Béné, M, Buccisano, F, Cloos, J, Grimwade, D, Haferlach, T, Hills, R, Hourigan, C, Jorgensen, J, Kern, W, Lacombe, F, Maurillo, L, Preudhomme, C, Van Der Reijden, B, Thiede, C, Venditti, A, Vyas, P, Wood, B, Walter, R, Döhner, K, Roboz, G, Ossenkoppele, G

“…American Society of Hematology…”

Results of a phase 2 trial of the monocyte-targeted histone deacetylase inhibitor tefinostat (CHR-2845) in chronic myelomonocytic leukemia (CMML) - the UK monocle study by Vyas, P, Hills, R, Knapper, S, Dennis, M, Drummond, M, Dillon, R, Pocock, C, Culligan, D, Wiseman, D, Zabkiewicz, J, Hodges, M, Cargo, C, Taylor, J, Upton, L, Wright, M, Bowen, D

“…American Society of Hematology…”

CIP2A- and SETBP1-mediated PP2A inhibition reveals AKT S473 phosphorylation to be a new biomarker in AML by Lucas, C, Scott, L, Carmell, N, Holcroft, A, Hills, R, Burnett, A, Clark, R

“…American Society of Hematology: Blood Advances…”